Safeguard Scientifics Q3 2022 net loss $3.2M vs prior-year net income $18.3M

SAFEGUARD SCIENTIFICS INC

2022-Q3 EPS reported -$0.57

Received $5.3M initial cash proceeds from Lumesis acquisition, recording a gain of $4.7M.
Funded $1.6M convertible note in Syapse's $35M growth capital round; capital to expand real-world insights for cancer.
Trailing 12-month revenues for eight portfolio companies were $139M, up 10.7% YoY.
Repurchased 84,261 shares in Q3 at avg $4.00; YTD repurchases 453,535 shares for $2.1M.
Operating costs reduced: G&A expenses $1.4M vs $1.6M in prior-year quarter.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SAFEGUARD SCIENTIFICS INC reported three and nine months ended September 30, 2022 results: net income Net loss for the three months ended September 30, 2022 was $3.2 million, or $0.19 per share, compared with a net income.

Period: three and nine months ended September 30, 2022
Net income: Net loss for the three months ended September 30, 2022 was $3.2 million, or $0.19 per share, compared with a net income
Result: reported results

Exact text from the filing

o Net loss for the three months ended September 30, 2022 was $3.2 million, or $0.19 per share, compared with a net income of $18.3 million, or $0.88 per share, for the same period in 2021.

View on SEC.gov

22 earnings releases filed in the last 30 days. Browse all earnings releases →

SAFEGUARD SCIENTIFICS INC filing history →

Source: SEC EDGAR

accession 0001437749-22-025767

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.